In addition, we found that most HLA-related genes and PDCD1 expressed at higher levels in the high-risk group, which was in accordance with the current increasing evidence regarding solid tumors suggesting that more HLA presentation increased the recognition of tumor-associated antigens in HLA and in turn increased the success of immune checkpoint inhibitor therapy (Rizvi et al., 2015; Lin W. Y. et al., 2021). The gene discussed is PDCD1; the disease is neoplasm.